Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution

Kozlov, Roman; Синопальников, А. И.; Зайцева, О В; Zyryanov, S. K.; Карпова, Е. П.; Радциг, Е Ю; Зайцева, С В; Локшина, Э. Э.; Stetsyuk, O.U.; Andreeva, Irina V.

doi:10.47407/kr2021.2.1.00036

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Рекомендуется использовать амоксициллин в качестве препарата первого выбора для исходно здоровых детей любого возраста с ВП (предположительно бактериальной этиологии) в амбулаторных условиях или в рамках дневного стационара [2,[71][72][73][74]. Приоритет амоксициллина в качестве стартовой терапии в дозе 45-90 мг/ кг/ сут внутрь (максимально 2 г/сут) в 2-3 приема (для детей старше 12 лет или с массой тела > 40 кг -1,5-3 г/сут в 2-3 приема) [26] В качестве альтернативы (при аллергии на макролиды) рекомендовано рассмотреть назначение доксициклина (для детей старше 8 лет!) [78] (УУР -С; УДД -5).…”

Section: консервативное лечение пневмонии антибактериальная терапия в...unclassified

“…В большинстве случаев рекомендуется продолжать АБТ при пневмонии в течение 7-10 дней с целью достижения оптимального эффекта терапии. Возможны и более короткие (5-6 дней), и более длительные курсы АБТ в зависимости от клинической ситуации [2,26,88] (УУР -А; УДД -2). Единого мнения по длительности АБТ при ВП у детей нет.…”

Section: консервативное лечение пневмонии антибактериальная терапия в...unclassified

See 1 more Smart Citation

Modern approaches at the management of children with community-acquired pneumonia

et al. 2023

Self Cite

View full text Add to dashboard Cite

Experts of The Union of Pediatricians of Russia have developed current clinical guidelines for management of children with community-acquired pneumonia, which were approved by the Scientific and Practice Council of Ministry of Public Health of the Russian Federation in January 2022. Particular attention is paid to the etiological structure, modern classification, diagnostic tests and flagship approaches to antibacterial therapy of community-acquired pneumonia in children based on the principles of evidentiary medicine.

show abstract

Section: консервативное лечение пневмонии антибактериальная терапия в...unclassified

Modern approaches at the management of children with community-acquired pneumonia

et al. 2023

Self Cite

View full text Add to dashboard Cite

show abstract

Current guidelines for the selection of an antibacterial drug in children with community-acquired pneumonia

Зайцева

Zaytseva

2022

Medicinskij sovet

View full text Add to dashboard Cite

The COVID-19 pandemic has affected the incidence of acute respiratory infections in the modern world. Despite the growing etiological significance of viruses in the structure of infectious diseases, the importance of bacterial pathogens in the development of respiratory pathology remains. The risk of unreasonable prescription of antibacterial drugs increases. The irrational use of antibacterial drugs has affected the spread of microorganisms with high resistance to antibiotics. The article presents current knowledge on the role of the most common pathogens of community-acquired pneumonia in children, data concerning the S. pneumoniae strain with reduced sensitivity and resistance to penicillin, macrolides. Information about isolates of S. Pneumoniae with decreased susceptibility to third-generation parenteral cephalosporins (cefotaxime and ceftriaxone) have appeared. The number of β-lactamase-producing strains of H. influenzae resistant to unprotected aminopenicillins is rising. The main steps of the diagnostic process of community-acquired pneumonia approved in the clinical guidelines for community-acquired pneumonia in children in 2022, which were adopted by the Russian Ministry of Health, are considered. This document sets out clear algorithms for diagnosing and selecting antibacterial therapy in children on an outpatient basis. Algorithms for selecting initial antibacterial therapy in outpatient settings are also proposed. In most cases, S. pneumoniae is a causative agent of community-acquired pneumonia in children, which defines the selection of an initial antibacterial drug. According to the clinical guidelines, oral amoxicillin at a standard dose of 45–55 mg/kg/day given in 2–3 divided doses is such a drug for children aged 3 months and older. Particular attention is paid to amoxicillin in the form of dispersible tablets.

show abstract

Key issues in selecting an antibacterial drug for the treatment of acute respiratory infections in children: A review

2023

View full text Add to dashboard Cite

Аcute respiratory diseases in children remain an urgent problem in pediatric practice. Most respiratory infections are due to viruses, but some may be due to bacterial pathogens or associations. During the pandemic of a coronavirus infection the number of unjustified prescriptions of antibiotics increased, which significantly complicated the situation with drug resistance of microorganisms and changed the strategy for choosing a starting antibacterial drug in children. Under the current circumstances, timely diagnosis of bacterial inflammation and the adequate choice of drug are the key issues in the practice of a pediatrician. On an outpatient basis it is important for a pediatrician to determine the indications timely and empirically prescribe an effective antibacterial drug. In Russia, in recent years, Federal Clinical Guidelines for various nosologies have been approved, defining indications for systemic antibiotic therapy. According to clinical guidelines, amoxicillin is the first-line antibiotic for most bacterial acute respiratory infections. In addition, there are cohorts of children who are expected to have risk factor as drug-resistant organisms and these children are eligible for protected amoxicillin as a first-line medication. The indications for prescribing macrolides and third-generation oral cephalosporins have fundamentally changed. The article presents the defining indications for systemic antibiotic therapy and the features of the choice of the starting antibacterial drug in children with acute respiratory infections.

show abstract

Inhibitor-protected amoxicillin with increased amoxicillin content and active ingredients ratio of 14:1: the use for treatment of community-acquired respiratory infections and ENT infections in children. Expert Council Resolution

Cited by 3 publications

References 0 publications

Modern approaches at the management of children with community-acquired pneumonia

Modern approaches at the management of children with community-acquired pneumonia

Current guidelines for the selection of an antibacterial drug in children with community-acquired pneumonia

Key issues in selecting an antibacterial drug for the treatment of acute respiratory infections in children: A review

Contact Info

Product

Resources

About